Cardiotoxicity induced by tyrosine kinase inhibitors

References

• van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251
   PubMedGoogle Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 355: 172–87
   Google Scholar
• Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935–42
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908–16
   PubMed Web of Science ®Google Scholar
• Khan MA. Effects of myotoxins on skeletal muscle fibers. Prog Neurobiol 1995; 46: 541–60
   PubMedGoogle Scholar
• Sanders EJ, Wride MA. Ultrastructural identification of apoptotic nuclei using the TUNEL technique. Histochem J 1996; 28: 275–81
   PubMedGoogle Scholar
• Dick JR, Lopaschuk GD. AMPK alterations in cardiac physiology and pathology: Enemy or ally?. J Physiol 2006; 574: 95–112
   PubMedGoogle Scholar
• Steinberg SF. Distinctive activation mechanisms and functions for protein kinase C delta. Biochem J 2004; 384: 449–59
   PubMed Web of Science ®Google Scholar
• Perik PJ, Rikhof B, de Jong FA, Verweij J, Gietema JA, van der Graaf WT. Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity. Ann Oncol 2008; 19: 359–61
   PubMed Web of Science ®Google Scholar
• Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett 2006; 243: 16–22
   PubMed Web of Science ®Google Scholar
• Tiribelli M, Colatutto A, Marin L, Barbina G, Qualizza U, Damiani D, et al. Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy. Am J Hematol 2008; 83: 517–8
   PubMedGoogle Scholar
• Verweij J, Casali PG, Kotasek D, Le Cesne A, Reichard P, Judson IR, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: Analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007; 43: 974–8
   PubMed Web of Science ®Google Scholar
• Brien SG O, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004
   PubMedGoogle Scholar
• Li B, Wang X, Rasheed N, Hu Y, Boast S, Ishii T, et al. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev 2004; 18: 1824–37
   PubMedGoogle Scholar
• Fernandez A, Sanguino A, Peng Z, Ozturk E, Chen J, Crespo A, et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007; 117: 4044–54
   PubMed Web of Science ®Google Scholar
• Aoki H, Kang PM, Hampe J, Yoshimura K, Noma T, Matsuzaki M, et al. Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem 2002; 277: 10244–50
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305(5682)399–401
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007; 109: 5143–50
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah N, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–41
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Nilotinib therapy in chronic myelogenous leukemia. Drugs Today 2007; 43: 691–702
   PubMedGoogle Scholar
• Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368(9544)1329–38
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24
   PubMed Web of Science ®Google Scholar
• Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370(9604)2011–9
   PubMed Web of Science ®Google Scholar
• Hsieh PC, MacGillvray C, Gannon J, Cruz FU, Lee RT. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 2006; 114: 637–44
   PubMed Web of Science ®Google Scholar
• Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, et al. Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500–8
   PubMed Web of Science ®Google Scholar
• Telli ML, Witteles RM, Fisher GA, Srinivas S. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008; 19: 1613–8
   PubMed Web of Science ®Google Scholar
• Van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G, et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 2008; 99: 259–65
   PubMed Web of Science ®Google Scholar
• Bayer Pharmaceuticals. Nexavar (sorafenib) prescribing information. 2009, Available from:, http://www.univgraph.com/bayer/inserts/nexavar.pdf.
   Google Scholar
• Strumberg D, Clark JW, Awada A, Moore MJ, Richly H, Hendlisz A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007; 12: 426–37
   PubMed Web of Science ®Google Scholar
• Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125–34
   PubMed Web of Science ®Google Scholar
• Sablin, MP, Bouaita, L, Balleguier, C, Gautier, J, Celier, C, Balcaceres, JL, , et al. Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients. J Clin Oncol 2007;25(18 Suppl)5038, (Abstract).
   PubMedGoogle Scholar
• Mego M, Reckova M, Obertova J, Sycova-Mila Z, Brozmanova K, Mardiak J. Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma. Ann Oncol 2007; 18: 1906–7
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204–12
   PubMed Web of Science ®Google Scholar
• Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, et al. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 2007; 12: 191–200
   PubMed Web of Science ®Google Scholar
• Muslin AJ. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 2005; 15: 225–9
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Watanabe T, Nishida K, Kashiwase K, Higuchi Y, Takeda T, et al. Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis. J Clin Invest 2004; 114: 937–43
   PubMed Web of Science ®Google Scholar
• Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 2005; 115: 2108–18
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006; 355: 2733–43
   PubMed Web of Science ®Google Scholar
• Burris HA. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004; 3(9 Suppl)10–5
   Google Scholar
• Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304(5676)1497–500
   PubMed Web of Science ®Google Scholar